This Article Full Text Full Text (PDF) All Versions of this Article: 34/6/1431    most recent 01.STR.0000071108.00234.0Ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kernan, W. N. Articles by Horwitz, R. I. Search for Related Content PubMed PubMed Citation Articles by Kernan, W. N. Articles by Horwitz, R. I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Stroke Transient Ischemic Attack Related Collections Cerebrovascular disease/stroke Type 2 diabetes Glucose intolerance Other Treatment

(Stroke. 2003;34:1431.)
© 2003 American Heart Association, Inc.

Original Contributions

Pioglitazone Improves Insulin Sensitivity Among Nondiabetic Patients With a Recent Transient Ischemic Attack or Ischemic Stroke

Walter N. Kernan, MD; Silvio E. Inzucchi, MD; Catherine M. Viscoli, PhD; Lawrence M. Brass, MD; Dawn M. Bravata, MD; Gerald I. Shulman, MD, PhD; James C. McVeety, MD Ralph I. Horwitz, MD

From the Departments of Internal Medicine (W.N.K., S.E.I., C.M.V., D.M.B., R.I.H.), Neurology (L.M.B., J.C.M.), Cellular and Molecular Physiology (G.I.S.), and Epidemiology and Public Health (L.M.B., R.I.H.), Yale School of Medicine; Howard Hughes Medical Institute (G.I.S); and Veterans Affairs Connecticut Healthcare System (L.M.B., D.M.B.), New Haven, Conn.

Reprint requests to Walter N. Kernan, MD, Department of Medicine, Yale University School of Medicine, PO Box 208025, New Haven, CT 06520-8025. E-mail Walter.Kernan{at}Yale.Edu

Background and Purpose— The aim of this study was to determine the effectiveness of pioglitazone compared with placebo for improving insulin sensitivity among nondiabetic patients with a recent transient ischemic attack (TIA) or nondisabling ischemic stroke and impaired insulin sensitivity.

Methods— Eligible subjects were men and women >45 years of age who had no history of diabetes, fasting glucose <7.0 mmol/L, and impaired insulin sensitivity according to an index calculated from insulin and glucose blood levels obtained during an oral glucose tolerance test. Eligible subjects were randomized to pioglitazone 45 mg/d or placebo. After 3 months of therapy, the glucose tolerance test was repeated.

Results— Between July 2000 and June 2001, we performed oral glucose tolerance tests on 75 patients with no history of diabetes, among whom 36 (50%) were found to have impaired insulin sensitivity and fasting glucose <7.0 mmol/L. Among these 36, 20 consented to the trial. Patients assigned to pioglitazone (n=10) and placebo (n=10) were similar in insulin sensitivity, age, obesity, and index event (stroke compared with TIA), but patients assigned to pioglitazone were less likely to be male (4 compared with 9). The mean proportional increase in insulin sensitivity was 62% among patients assigned to pioglitazone compared with a -1% decline among patients assigned to placebo (P=0.0006). Mean C-reactive protein concentration declined from 0.30 to 0.20 mg/L among patients assigned to pioglitazone and increased from 0.41 to 0.45 mg/L among patients assigned to placebo (P=0.06 for comparison of mean change).

Conclusions— Pioglitazone is effective for improving insulin sensitivity among patients with recent TIA or stroke and impaired insulin sensitivity.

Key Words: cerebrovascular disorders • cerebral ischemia, transient • insulin • insulin resistance • pioglitazone • prevention • randomized controlled trials • risk factors • stroke, ischemic

This article has been cited by other articles:

				D. Sander, K. Sander, and H. Poppert Review: Stroke in type 2 diabetes The British Journal of Diabetes & Vascular Disease, September 1, 2008; 8(5): 222 - 229. [Abstract] [PDF]

				J. F. Arenillas, M. A. Moro, and A. Davalos The Metabolic Syndrome and Stroke: Potential Treatment Approaches Stroke, July 1, 2007; 38(7): 2196 - 2203. [Full Text] [PDF]

				K. M. Utzschneider and S. E. Kahn The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4753 - 4761. [Abstract] [Full Text] [PDF]

				K. Tsuda Hyperinsulinemia and Membrane Microviscosity of Erythrocytes as Risk Factors for Stroke in Patients With Impaired Glucose Tolerance Stroke, November 1, 2006; 37(11): 2657 - 2657. [Full Text] [PDF]

				R. M. Najarian, L. M. Sullivan, W. B. Kannel, P. W. F. Wilson, R. B. D'Agostino, and P. A. Wolf Metabolic Syndrome Compared With Type 2 Diabetes Mellitus as a Risk Factor for Stroke: The Framingham Offspring Study Arch Intern Med, January 9, 2006; 166(1): 106 - 111. [Abstract] [Full Text] [PDF]

				T. Shimazu, I. Inoue, N. Araki, Y. Asano, M. Sawada, D. Furuya, H. Nagoya, and J. H. Greenberg A Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Reduces Infarct Size in Transient but Not in Permanent Ischemia Stroke, February 1, 2005; 36(2): 353 - 359. [Abstract] [Full Text] [PDF]

				W. N. Kernan, C. M. Viscoli, S. E. Inzucchi, L. M. Brass, D. M. Bravata, G. I. Shulman, and J. C. McVeety Prevalence of Abnormal Glucose Tolerance Following a Transient Ischemic Attack or Ischemic Stroke Arch Intern Med, January 24, 2005; 165(2): 227 - 233. [Abstract] [Full Text] [PDF]

				M. Recasens, A. Lopez-Bermejo, W. Ricart, J. Vendrell, R. Casamitjana, and J. M. Fernandez-Real An Inflammation Score Is Better Associated with Basal than Stimulated Surrogate Indexes of Insulin Resistance J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 112 - 116. [Abstract] [Full Text] [PDF]

				K. Tsuda, W. N. Kernan, S. E. Inzucchi, and C. M. Viscoli Insulin and Membrane Microviscosity of Erythrocytes as Risk Factors for Stroke * Response Stroke, December 1, 2003; 34 (12): e225 - e226. [Full Text] [PDF]